<SEC-DOCUMENT>0001213900-24-051263.txt : 20240610
<SEC-HEADER>0001213900-24-051263.hdr.sgml : 20240610
<ACCEPTANCE-DATETIME>20240610164047
ACCESSION NUMBER:		0001213900-24-051263
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240610
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240610
DATE AS OF CHANGE:		20240610

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MoonLake Immunotherapeutics
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39630
		FILM NUMBER:		241033354

	BUSINESS ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		41 41 510 8022

	MAIL ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp
		DATE OF NAME CHANGE:	20200818
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0207582-8k_moonlake.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:MLTX="http://moonlaketx.com/20240610">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_MLTX_moonlaketx.com_20240610 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20240610_20240610 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001821586 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000004" name="dei:EntityCentralIndexKey">0001821586</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mltx-20240610.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-06-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-10</xbrli:startDate>
        <xbrli:endDate>2024-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20240610__20240610_zSi1WJh3e7h9"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PURSUANT TO SECTION 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_907_edei--DocumentPeriodEndDate_c20240610__20240610_zQpEcUTxzcf4"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 10, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20240610__20240610_zGeszRKj9O2j"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000011" name="dei:EntityRegistrantName">MOONLAKE IMMUNOTHERAPEUTICS</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240610__20240610_zE30dWr4iTl7"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt-sec:edgarprovcountryen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Cayman Islands</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20240610__20240610_z7zdEtlwmjyk"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000013" name="dei:EntityFileNumber">001-39630</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20240610__20240610_zPN9zKG7Rmji"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1711963</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer <br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20240610__20240610_zYNyYygK3BWd"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000015" name="dei:EntityAddressAddressLine1">Dorfstrasse 29</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20240610__20240610_zUV3PtQLYQT2"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000016" name="dei:EntityAddressPostalZipCode">6300</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressCityOrTown_c20240610__20240610_zkDosr0bgh7g"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000017" name="dei:EntityAddressCityOrTown">Zug</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_907_edei--EntityAddressCountry_c20240610__20240610_zcFrwsvxy1U1"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt-sec:countrynameen" id="Fact000018" name="dei:EntityAddressCountry">Switzerland</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices and Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_905_edei--CityAreaCode_c20240610__20240610_z15GDzyc37Ba"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000019" name="dei:CityAreaCode">41</ix:nonNumeric></span> <span id="xdx_90D_edei--LocalPhoneNumber_c20240610__20240610_zCvNI5MdZlZ6"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000020" name="dei:LocalPhoneNumber">415108022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="background-color: white"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="background-color: white">(Former Name
or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2 below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20240610__20240610_zVtaLvzAcTb4"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20240610__20240610_zmsEC4QhqPg3"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementTenderOffer_c20240610__20240610_zAHrxAxKUWcd"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20240610__20240610_zxXhB5bWNZS2"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="white-space: nowrap; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="white-space: nowrap; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20240610__20240610_zvHtoyjAxFog"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000025" name="dei:Security12bTitle">Class A ordinary share, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20240610__20240610_z1rvZEY4Sf7e"><ix:nonNumeric contextRef="AsOf2024-06-10" id="Fact000026" name="dei:TradingSymbol">MLTX</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20240610__20240610_zx3zGaWGSD4j"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20240610__20240610_z5EdCQBpejH6"><ix:nonNumeric contextRef="AsOf2024-06-10" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2024, MoonLake
Immunotherapeutics (the &#8220;Company&#8221;) issued a press release announcing the successful outcome of its end-of-Phase 2 interactions
with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), as well as positive feedback from its interactions with the E.U. European
Medicines Agency (the &#8220;EMA&#8221;), with both regulatory bodies unanimously supporting the Company&#8217;s proposed approach for
advancing its Phase 3 program of the Nanobody<sup>&#174; </sup>sonelokimab (&#8220;SLK&#8221;) in psoriatic arthritis (&#8220;PsA&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item
7.01 of this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of
1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Exchange Act or the Securities Act of 1933, regardless of any general incorporation language in such
filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2024, the Company
announced the successful outcome of its end-of-Phase 2 interactions with the FDA, as well as positive feedback from its interactions with
the EMA, with both regulatory bodies unanimously supporting the Company&#8217;s proposed approach for advancing its Phase 3 program of
SLK in PsA. The Phase 3 program, named IZAR, is expected to enroll around 1,500 patients and, in combination with data from the Phase
2 ARGO trial, is designed to support a Biologics License Application and E.U. Marketing Authorization Application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form 8-K and the press
release furnished as Exhibit 99.1 contain certain &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company&#8217;s expectations,
hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for and timing
of clinical trials, including the topline primary endpoint readout for the Phase 3 IZAR program, the trial design and patient enrollment
across the IZAR-1 and IZAR-2 trials, the initiation of the Phase 3 program in PsA, the efficacy and safety of SLK for the treatment of
hidradenitis suppurativa and PsA, including in comparison to existing standards or care or other competing therapies, clinical trials
and research and development programs and the anticipated timing of the results from those studies and trials. In addition, any statements
that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions,
are forward looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. These statements
reflect our plans, estimates, and expectations, as of the date of this Current Report on Form 8-K. These statements involve known and
unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements
expressed or implied in this Current Report on Form 8-K. Actual results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of these risks and uncertainties. Additional risks and factors are identified under &#8220;Risk
Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings with the
Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <i>Exhibits</i>. The following exhibits are
being furnished herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit&#160;Number</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Exhibit Title or Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><a href="ea020758201ex99-1_moonlake.htm"><span style="font-size: 10pt"><span style="text-decoration: none">Press Release, dated June 10, 2024</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>MOONLAKE IMMUNOTHERAPEUTICS</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">Date: <b>June 10, 2024</b></span></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt">/s/ Matthias Bodenstedt&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name:</span></td>
    <td><span style="font-size: 10pt">Matthias Bodenstedt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZS03jz6JLixaxihQRt8FOJdhmyiT+HclbGlvEYWAY3vveE2IkclqZBhlOi7KAA7Zdoz1CiTUy2jMGR7bepBBuiRfjPGvr+/cHZhQYDMwsVuochN56Nw6rFOR8nMixmoKcpFLBfiuir56RrU2F1hvdgLYV7Jk6Nug1v4aEg36SpfbVVx2RnSGbQhLLQX6DkomCHd31g/jqoCgyEY36iUTOdOuCa/n0aL8kLBtsQ50b6P9GHwLfSoY= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020758201ex99-1_moonlake.htm
<DESCRIPTION>PRESS RELEASE, DATED JUNE 10, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake
Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody<SUP>&reg;
</SUP>sonelokimab in Psoriatic Arthritis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Builds
                                            upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for
                                            sonelokimab in hidradenitis suppurativa (HS), which has started recruitment</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clarified
                                            path for PsA Phase 3 program with study design, patient population and endpoints agreed &ndash;
                                            program is called IZAR and two trials are planned with one focusing on bio-na&iuml;ve patients
                                            and radiographic progression (IZAR-1) and another on TNF-IR patients (IZAR-2)</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
                                            main dose to be tested will be 60mg, and the 120mg dose will also be tested, with risankizumab
                                            as a reference arm (in IZAR-2)</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Total
                                            Phase 3 population of approximately 1,500 patients to be complemented by Phase 2 population
                                            for registration</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
                                            3 trial design in line with the Company&rsquo;s communications and guidance </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>First
                                            patient expected to be randomized in Q4 2024; primary endpoint readout expected end-2026</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZUG,
Switzerland,</B> June 10, 2024 &ndash; MoonLake Immunotherapeutics (NASDAQ:MLTX) (&ldquo;MoonLake&rdquo;), a clinical-stage biotechnology
company focused on creating next-level therapies for inflammatory diseases, today announced the successful outcome of its end-of-Phase
2 interactions with the U.S. Food and Drug Administration (FDA), as well as positive feedback from its interactions with the E.U. European
Medicines Agency (EMA), with both regulatory bodies unanimously supporting MoonLake&rsquo;s proposed approach for advancing its Phase
3 program of the Nanobody<SUP>&reg;</SUP> sonelokimab in psoriatic arthritis (PsA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 3 program, named IZAR, is expected to enroll around 1,500 patients and in combination with data from the Phase 2 ARGO trial is
designed to support both a Biologics License Application (BLA) and E.U. Marketing Authorization Application. Two global, randomized,
double blind, placebo-controlled trials are planned (IZAR-1 and IZAR-2) to evaluate the efficacy and safety of the Nanobody<SUP>&reg;
</SUP>sonelokimab over one year. IZAR-1 will enroll a biologic na&iuml;ve population and include an evaluation of radiographic progression,
while IZAR-2 will enroll a TNF-IR population and will be the first trial to include a risankizumab active reference arm. The IZAR program
will assess a 60mg sonelokimab dose as well as a 120mg sonelokimab dose. The primary endpoint (ACR50) compared to placebo and key secondary
endpoints for both trials will read out at week 16. The readout of the primary endpoint is anticipated at the end of 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said:</B> <I>&ldquo;The recent regulatory milestones for
PsA mark the second such significant achievement for MoonLake building on the positive FDA and EMA feedback for HS earlier this year.
These regulatory outcomes provide a clear roadmap for PsA and, by the end of 2024, we will have independently commenced three Phase 3
programs addressing two inflammatory indications that are under diagnosed and underserved. This progress is a testament to our specialized
expertise and steadfast commitment to advancing the field of inflammation and immunology.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-
Ends &ndash;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Psoriatic Arthritis </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psoriatic
arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis primarily affecting the peripheral joints.
The clinical features of PsA are diverse, involving pain, swelling, and stiffness of the joints, which can result in restricted mobility
and fatigue. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. The symptom burden
of PsA can have a substantial negative impact on patient quality of life. Although the exact mechanism of disease is not fully understood,
evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
IZAR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IZAR-1
and IZAR-2 are planned global, randomized, double-blind, placebo-controlled Phase 3 trials that will be designed to evaluate the efficacy
and safety of sonelokimab compared with placebo in a total of approximately 1,500 adults with active PsA, with a primary endpoint of
superiority to placebo in ACR 50 response at Week 16. IZAR-1 will enroll a biologic-na&iuml;ve population and include an evaluation of
radiographic progression, while IZAR-2 will enroll a TNF-experienced population &mdash; reflecting patients commonly seen in clinical
practice &mdash; and will be the first PsA trial to include a risankizumab active reference arm. Both trials will also include a range
of secondary endpoints reflecting the multiple disease manifestations characteristic of PsA, including skin and nail outcomes, multidomain
endpoints, and patient-reported outcome measures such as pain and quality of life assessments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Sonelokimab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
(M1095) is an investigational ~40 kDa humanized Nanobody<SUP>&reg;</SUP> consisting of three VHH domains covalently linked by flexible
glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the
IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab
at sites of inflammatory edema.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
is being assessed in two lead indications, HS and psoriatic arthritis (PSA), and the Company is pursuing other indications in dermatology
and rheumatology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
HS, sonelokimab is being assessed in the Phase 3 trials, VELA-1 and VELA-2, following the successful outcome of MoonLake&rsquo;s end-of-Phase
2 interactions with the FDA and as well as positive feedback from its interactions with the EMA announced in February 2024. In June 2023,
topline results of the MIRA trial (NCT05322473) at 12 weeks showed that the trial met its primary endpoint, the Hidradenitis Suppurativa
Clinical Response (HiSCR)75, which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials,
setting a landmark milestone. In October 2023, the full dataset from the MIRA trial at 24 weeks showed that maintenance treatment with
sonelokimab led to further improvements in HiSCR75 response rates and other high threshold clinical and patient relevant outcomes. The
safety profile of sonelokimab in the MIRA trial was consistent with previous trials with no new safety signals detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
PsA, Phase 3 initiation is anticipated in Q4 2024 following the announcement in March 2024 of the full dataset from the global Phase
2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody<SUP>&reg;</SUP> sonelokimab over 24 weeks in patients
with active PsA. Significant improvements were observed across all key outcomes, including approximately 60% of patients treated with
sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed
the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion
of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving ACR50 response compared to those on placebo at week
12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab
in the ARGO trial was consistent with previous trials with no new safety signals detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 2 trial is expected to be initiated in 2024 for palmo-plantar pustulosis (PPP), a debilitating inflammatory skin condition affecting
a significant number of patients. In addition, a Phase 3 trial is expected to initiate in juvenile HS, a condition that typically manifests
at this early stage of a patient&rsquo;s life, and the period in which irreversible damage and inflammatory remission is most critical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
will also be assessed in seronegative spondyloarthritis with Phase 2 trials in radiographic and non-radiographic axial spondyloarthritis
(axSpA) and PsA expected to start in 2024. The trials are set to incorporate innovative designs that enhance traditional clinical outcomes
with contemporary tissue and cellular imaging techniques.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
has also been assessed in a randomized, placebo-controlled Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type
psoriasis. High threshold clinical responses (Investigator&rsquo;s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index
90/100) were observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety
profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an earlier Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal
skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196&ndash;203).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nanobodies<SUP>&reg;</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanobodies<SUP>&reg;
</SUP>represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding
variable regions of heavy-chain-only antibodies (VHH). Nanobodies<SUP>&reg;</SUP> have a number of potential advantages over traditional
antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their
ability to be designed into multivalent therapeutic molecules with bespoke target combinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms Nanobody<SUP>&reg;</SUP> and Nanobodies<SUP>&reg;</SUP> are trademarks of Ablynx, a Sanofi company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Hidradenitis Suppurativa</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hidradenitis
suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory
skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result
in irreversible tissue destruction and scarring. The disease affects 0.05&ndash;4.1% of the global population, with three times more
females affected than males. Real-world data in the US indicates that at least 2 million unique patients have been diagnosed with and
treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity
exceeding $10bn by 2035. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher
morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17-mediated inflammation
as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
MoonLake Immunotherapeutics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MoonLake
Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody<SUP>&reg;
</SUP>for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting
the IL-17A/A, IL-17A/F, and IL17F/F dimers that drive inflammation. The company&rsquo;s focus is on inflammatory diseases with a major
unmet need, including hidradenitis suppurativa and psoriatic arthritis &ndash; conditions affecting millions of people worldwide with
a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information
is available at www.moonlaketx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Statement Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains certain &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake&rsquo;s expectations, hopes,
beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for and timing of clinical
trials, including the topline primary endpoint readout for the Phase 3 IZAR program, the trial design and patient enrollment across the
IZAR-1 and IZAR-2 trials, the initiation of the Phase 3 program in PsA, the efficacy and safety of sonelokimab for the treatment of HS
and PsA, including in comparison to existing standards or care or other competing therapies, clinical trials and research and development
programs and the anticipated timing of the results from those studies and trials. In addition, any statements that refer to projections,
forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements.
The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo; and similar expressions may identify forward-looking statements, but
the absence of these words does not mean that statement is not forward looking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the
case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result
of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake&rsquo;s business
in general and limited operating history, difficulty enrolling patients in clinical trials, state and federal healthcare reform measures
that could result in reduced demand for MoonLake&rsquo;s product candidates and reliance on third parties to conduct and support its
preclinical studies and clinical trials and the other risks described in or incorporated by reference into MoonLake&rsquo;s Annual Report
on Form 10-K for the year ended December 31, 2023 and subsequent filings with the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will
be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance
on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety
by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions
to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any
such statement is based.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake
Immunotherapeutics Media</B><BR>
Patricia Sousa<BR>
media@moonlaketx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ICR
Consilium</B><BR>
Mary-Jane Elliott, Namrata Taak, Ashley Tapp<BR>
Tel: +44 (0) 20 3709 5700<BR>
MoonLake@consilium-comms.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V ,0# 2(  A$! Q$!_\0
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8@ HHHH ****0!1113 ****0!1113 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y ,0# 2(  A$! Q$!_\0
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M,M!\$>&+$!Q$VIZ_J$-C%<WDD<<K6VG6"2O?:G>&-H[+3[:YNY1Y<+D>X?\
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M60O;&$W-HEW;-/#OB$\1;>/Y ?\ @SWS_P )C^W-UQ_PC'P,]=N?[6^)>?\
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MO%+%/%'/!)'-#-&DL,T3K)%+%(H>.2.1"4>-T(9'4E64AE)!!KF_%WCCP5X
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M_!&_]DW]ICX3>%_C/^TC^W7;NW[8GQ\UWPKX.\0^?JFG:O\ V!\'?@7X;L_
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mltx-20240610.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaCCCaPtyJ1xOYkxuG9/fZk6/yksy4CNdCh8C7yGYUMI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:MLTX="http://moonlaketx.com/20240610" elementFormDefault="qualified" targetNamespace="http://moonlaketx.com/20240610">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://moonlaketx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20240610_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20240610_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mltx-20240610_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mltx-20240610_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://moonlaketx.com/role/Cover" xlink:href="mltx-20240610.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://moonlaketx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140636912496144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 10,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOONLAKE IMMUNOTHERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1711963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Dorfstrasse 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">415108022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary share, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"6L[I95$N-+P#@,JEP"*>_A_@:;*6/ADOXKT<)GABF!TF-/1<E6@N)GG4S:
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ %H7*6)>*NQS
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M4$L! A0#%     @ %H7*6 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  6A<I8.24E:>X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  6A<I8F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( !:%RECIWM#71@0  'D0   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  6A<I8GZ ;\+$"  #B#   #0              @ &)#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( !:%REB7BKL<P    !,"   +              "
M 64/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !:%REBJQ"(6,P$  "("   /
M              "  4X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  6
MA<I8)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  6A<I899!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0207582-8k_moonlake.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0207582-8k_moonlake.htm">ea0207582-8k_moonlake.htm</File>
    <File>mltx-20240610.xsd</File>
    <File>mltx-20240610_lab.xml</File>
    <File>mltx-20240610_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0207582-8k_moonlake.htm": {
   "nsprefix": "MLTX",
   "nsuri": "http://moonlaketx.com/20240610",
   "dts": {
    "inline": {
     "local": [
      "ea0207582-8k_moonlake.htm"
     ]
    },
    "schema": {
     "local": [
      "mltx-20240610.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mltx-20240610_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mltx-20240610_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://moonlaketx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207582-8k_moonlake.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207582-8k_moonlake.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-24-051263-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-051263-xbrl.zip
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M%>CY[OWYD>]]JA2ZV]=[IQ_&Y[VV_?6]Y$@>6_C$-UKZ0[/Z_U!+ P04
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M98O\7942612O>!<0<25;E\!-A],\(OCN3?Z*[RTN$X0>$^4.I"I,(B03%;.
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ME!C*3>DENLW0740!BH9<1 6#:<,>"KYI"-HF52VQS>>/I/D:]ZI'PB\)/=<
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M[[^(+]Y_//@!W^?YXOCR[/3=_P-02P,$%     @ %H7*6-L@V4G3"P  9@P
M  T   !I;6%G95\P,#$N:G!GG=1G5--=M@?@?TA(Z @$:1%0>A4QA"HH#B(H
M1$ 01& 47FD2! Q%JH46(5@H+RA1I(2 P%!"%5"ITB(0B 14BA2IB;108@;?
M-7/OE_EP[_S.V9_V/F>M9YVU#N<S9Q(X9'W.ZAP  H& OQ\L@#,.G 5XH% 8
ME)L'!H/Q\O+P"< %!?CY!:1$Q83A1Z3E9(]((Q#RBMHJ\L<T%1 (57TU39T3
M2"123L7PE(&NB?9)I.[O2T \O+P"_ *2@H*2ND<11W7_W^&\ T1X !30#@8=
M [A$0& 1$*<=D , $#?HKP#_"H@+#.&&PGAX^?@/!LB' "X0&,P% 7-S0R '
MW>B#/@ 1X18]>N(,5,SN.NQ8$%SWWI,\'@7SRO?B]H,,Q9,W@N_S\AV6D)22
M5E)645531^JA] T,C<[^S>*<Y7DK:X?+CDY7G%VN>GK]<=/;Q]<OY XV-"P\
MXNZ#A_$)B4G)N*?/TC,RL_[,SGF=7U!81"PFE515UY!KZ^H;&C^TM7=T=G5_
M[!D:IHZ,TCZ/T:>F9[[/SLTO_%AD_ES?V-S:9NWL_G:! ##HW_F/+I$#%Q<$
M H; ?KM 7&&_!T0@W$=/0$7/V,&N!XD=T[W' S=_DE?YGE?AI#U#_$;P(-]A
M1>24$O,W[2_9_PUV_[^2_0_L?UUT0  ,.G@\L A@!FQ/T%Z&TZ:+,J:N1&I@
M)1K_7.)#B9M]Q72-EUDR'3K7I@+$-9<5QTE?O12$+IXWJML07P\Q/GGR8(OV
M.7^OEBW8I>4]?+_G2-'"WR5'W''-+2<QO3MVG^?FQ%6E<(!>8R]^#I"&J%MR
M.12^U!$Z%(@^Y*<9E$8(O;Z#\C]N,T0^<F.F>_@6L2D=ZWRIUI1(QKA'&3"C
MX^M>HN*#':38HV.2T>9/_:G?V\Y^"36L0&%EY5CC99^[G_CK=!2?&<R%6\K+
M)4*;6]M^*0_MHXO*5K-N*Z4P>@?S35.,KW1KOL%WORLEO7>2E-^&UK[5F(Y<
MXUVJ7$2E6(O5AEM-.ZX*[TPW5$I*6IM0MY%$%Z*OG(?=Y3MEMC3GH16RC.6W
MP-OW9@(O^:V&5XB4^@P,4AW X*$7@@#<'E-(@0,U=A8 _'=E%Q;T UIPN]-0
MGX)^J0*N00OX.]77.&#GPK33F]W6-++E\4;CL#VDIQG60?Y7P#/6J%!RP80_
M_4M1EG][G:XZYM?"+P6G**?"*(_R!(C<"B]E;G[7Z=N'Y/P'TTY/A^HO?;W!
MA68B;P'[-M$*[*]R7Y8CQBD."Q3A<'];QD#V$?Q+ODX<=*ZK7R$V(BW$5=)@
M/@=$#/) ?1]O.@5YZF3R8)H#W O ;&2_M? 4[8C$Z%^#2(HIWWT9M.3.2V^I
M9[X==&7)N48XJT?C'#]NJI]FVT3AC?BV@\<:+#I>Z,WX^D1R@'?-+JO[>I%%
MW;.IZ9/$JOH!L[57(PON:O69E _TPG91I(.%OV+23,GC9O\>,^]-X\VM\?<_
MH;%KLW>S4EJ_VXS&+@UXL"&T[&2<X]BP[2K,D#'L3JVXM7JGS&^20KKZ,/LF
MIJI-=2*5Y97VH1$-7_*=H@B[^]WB1UKMU<AU'-VQBQ7U3WI+25QY>W3Z<Y+S
M4[J,X-E/'Q9UNMBC\\PRMZ#G[0338>3?%#__.(.5^2#,O?,SG0,L.#ZSZF'S
M-6<D1!UO&2T/P#Z/#MU<+5\)A'BU0/LZWYSN:M ;](LYP9A+Q6X%6+I4U[XD
M)<_*)#: B3/7](I*35,+]L]3 ]+65M8*O%18KKWNL658 IQ1FT$,CZ&R<S0>
M/4H:]7^4G6[<KR!0?=APT4;,>ONZ#+W+TCO6M_AJ87]N^Y5#!CT?Q1(<6#C*
MR+[=:Q_C<R32^-7JZ)$GG3,;[N3N,QB"&"MK2TO73+O+L2IS[L)ER?.S::ST
MT"\+ZNC$1J7,_-<<X(-5L87@*JG$N%?S9W%T:7W<(\*]TRL./9EUGZ)HGY8W
MF@-M1LM:!HN^G0D[-%EC*P/[-E3J%EYA7NE:C2VA6VQ9BDP$I@MK)74[K.%F
M]=BZXVVF>I^PJ4JB(YLR>9X1D+-^?6^(_@$_,KJNYDW92'?9L9Y/[_4VW2&X
MNB:-BLA/E#9$&)AXXVM4BYY+H&J-F^7:=[5;Y/:..]0U>4EA4SMG90NPX@^$
M2#$<0 *ST4HVK'334G8V>VAX"U,BJS.\@HR%AWLX5\<'K%YE!RCJI-X_/^::
M "Y7O^!Y<&!@@P-09<W8 L,I83&GQQ9<*^D-X]\0X=[H%E38W2_I^AIQW4-I
M60=_@_>^U8AV#85[@EQJA=@6M;Q5K0+568;7S;[L<\I\-F4C835$0]<.K^SG
MUH>&MTD)E\I^WR3AG)K4ZB(5K+7L>R+S L2I:,,D6Q%7Q4Y;</3):W5MT?9[
MCH.;AF1^8OU3+?MPNY=2/$VW-53:<C2E)3I2K0=&*&.VZ5460LL[H,)9V.VF
M.IV-+]<2X]<PF'(E!I466.2;12\<C,S8H]EDL'OJ&&)+U)%BGV4TJJO6Q5\Z
M)A\R-.9N87*I 6^E<-O1&2OUH^.FQ4PK/_JN9C[MS=7@<?-D2Y7A4QJ/F0Q\
M1Y3Q5*D-:LY&>\YI?7DYSBG'@';,Y*G1ILGZDL.$GQ/-R&7X#U9@J8RR&^%2
M[4-NC\"<IPG)+7G]I!_F%_&&LC57Q!F[;C>%!<GE1,](&=>)CT=:Z3W) B9P
MBLGDD08.<!-WK7""24F1%LBQ3)UKYHOI+ZYXD5@["5QGQTI/::TJD>MQT[ 3
M_6*E^16,?QB*;X:E1BD%3+.Y7*7^5%P,&^__JK\<D_%SM2YOT526^@U-7:'S
M4IDO&V?V>B)Q6_]PG#&(-,0$.3Y(*4^+97AT1*NXU> %[:<UCEA=$:K*):GL
M67\YL>)6-I]4DVHT@8X@T<^*N/50=%/;Q@FQ?*SEN* G:Y0RR16"NG<F48/H
MI9<4C;9AY3*5S<14MDR?->WI.2.?/;X\T/8*O/=JW?V&[T1,KO\G4T2440/3
M-$^<O7_\<)H85"G!9)T]LNGAX(8BQA>2"&3%NXGORW@WTJ!:U 6G '.T&:R\
M[[J9;:ST\OX93Q1QZLNY'L$6;+NP-,9 2@$Q^C!(TZ<85U*B R#XLL37JY^_
MF,"S.GNZ3G$ GHTP@D":>2M?S^B%0#7$5.V])QLFN'Z&<+SVOE[A -8XOH&Z
M6B"(?#>OGN^G'9T>4]1D8H>[-C JY!CY(C1YRNI5(/QLB:8]?7&[0OUU;8B,
M_#59(Z;+*,I4GT&5&ZO5^;PD'>49\*9.0EDJW[V' Z@)XC,63A5W^J[KU^_8
M=86'M!FE7&WN2C(Y$R*P6S.89"</L0@\'$(.H9F2S05A[;]$&PC'A<H(>07]
M&A>.Y/8EJ-1I!IO7"ETY5?K)Y]UF85];!@*5/=4<>)DIV-(P'48^5R6XI<%O
M[G+LYMY 7\RZ8X50>.BV%1.=3-9X)O&$A$8\OG7#5OR\<7UY*_P^_B:B>#;*
M[=57_Q"?-#]/KMY+^#FW9<ON5_,([)M4C]-,$UG3K'9IA-$=9J]79H=VX1^=
MDB\8@G<%)8N*1N\'79RF7:3M6Q4M2E_!+6^PM%22U/72^RA-IR(0GKA2'].C
M/VYKQ=4,D9$IM_"[%Q*2LRW-%V >A6&3-^+40B)@:N]9(1^,BC)F-,J"?VUJ
M?V^J%*'([YS.BKE=.L85#R:,R,9/HCSX%W-,:RKUZ16SC<G3AB<PG:,.>$F1
MG T!.W1V6@8"3A"GZ05PR41;_U(<1?[8[S>S3Q*UA<(;]_"2#CF!22%M6X'+
M;&GZ.1D;1H.W(P?PL<2WIH9%#5KJ!.>KG!T:/S=TO4J_3@+SXNTV=_9WSX\J
M!--TIV9Q?7Y>Y\;MA)H*46<9-Z<1E92T=()43"(9?NFY_2>T9^\F.JYV32U:
MQ3G<\]2QAK1P.=QTY21+Y(U)$T;O$1SM/#+6>DGU=5,^KB2C/-A6?=Y[:NT^
M'9IU[)J?;B^IAWA;=+]RGCU(8RHW*QMXWCNL.F@'#W"TBX,-X33P9"NKQ8$2
M7^><3)SZ!3[5UW'_H1YSP^TN<N%4"T 6< <P9^R?4$L#!!0    ( !:%RE@F
M/:K(*0,  .D+   1    ;6QT>"TR,#(T,#8Q,"YX<V2U5MMRVC 0?>],_T'U
MNQ&&W""03.M,,G0@R80DA;QTA"U @RPYDAS,WU?RA9N! &UYDG?/.;OKW95I
M7,<!!1]82,)9TW)*90M@YG&?L%'3>NG:W[MNJV6!ZZNO7X#^-;[9-K@EF/IU
M<,,]N\6&_!+<HP#7P1UF6"#%Q25X130R%GY+*!; Y4%(L<+:D4:J@]-2I>(!
MV]Y#]Q4SGXN7I]9<=ZQ4*.L03J?3$N,?:,K%1)8\'NPGV%5(17*N5H[+V6\_
M>H=(;TZ&[^&;/(^?2&^$V47TH]_KRU_(=5WTJ&8_G?BA/XFCNQH<ODW.X&PB
M9R?NO>^.+]SSV5W_I=-*0S:D-\8! KH93#8M4U]6WK1:XF($*^6R WN==C?!
M62FP'E/")IO@3JU6@XDWAQ:0\4#07+H*C7N ))XK:R_9@2=,*L2\%;ROYH1E
M\"E,G2M0LA%ZED))#O7Q&DYBKS3B'U [-+YRD@,C:8\0"N?@(9*#1#1SK("E
M4$6@-JZ#;#4+L=P(35TKA$[[N3?'!IPSBB98Q68J$USYS#&[17& F;KE(KC!
M0Q11G<I[A"@9$NQ;0"$QPLJ,F0R1AS_5RZ<5,<;U4.O-RBS&%H9$3^W<H$VF
MRW7!*7[6Z0-ST%NU+8AQ0Y?KN\$"Q&]:Z7%)+A?T\9 PD@3/]L@!MMF:R)2J
MCPFS =?!1:5(8O^!727G4&"IZ4E1;6W(^!ED-]=#U(OH4=1%?KN8F3U_E85W
MG*_3$QZ"9 WK9F":EB3F(K0RVUC@8=,*J(KMO*._==DE/5 YQ$38L89)C];?
M5!8XET#"*Z@4K@DMPD,L%-%3O707I*D39>B/2V& B2,M /]AY10-#JU<4S#]
MCR6WC7ZQU@9<W2W]O+Y_#5TN%PJPPBKONDO3KT";>XG4#HIYLG.>;4RV4[&K
M3BF6_B+30Y)8O('#DLAY1R2QY4;?%%]N@YM#,D+[!MWR9=@9=",'8JID;CDZ
MA>7OR%_DD,@<E,1*.WTEH)$PHA5;]['J;$_G,V;R+(\: H]'3(G9(8.P3,D?
MCNO&XA_ ?HW(\6D3S)^"8\,>,07%X)M&H %3-7W\ U!+ P04    "  6A<I8
M5X5=[/X*  " A@  %0   &UL='@M,C R-# V,3!?;&%B+GAM;,V=76_CN!6&
M[POT/[#N30N,XXFS+9#L9!<93[(P-INDL6>V[:)8T!+C"*')@)(3^]^7E$19
MHG@D)45)SL6,1WP/]5)\3%)?QY]^W&TH>B$B33@['QT??1PAPB(>)VQ]/OJZ
M&%\L9O/Y"*499C&FG)'S$>.C'W_XXQ^0_//I3^,QNDH(C<_0%QZ-Y^R!?X]N
M\(:<H9\((P)G7'R/OF&Z55OX54*)0#.^>:8D([*@V/$9^MO1=!JA\7A O=\(
MB[GX>C^OZGW,LN?T;#)Y?7T]8OP%OW+QE!Y%?#.LPD6&LVU:U?9Q]['\4X1_
MH@E[.E-_K7!*D#Q>+#W;I<GY2.VWW.WKR1$7Z\GTX\?CR3]_N5Y$CV2#QPE3
MQRTB(QVE:K'%'9^>GD[R4BUM*7<K0?4^3B;:3E6S+$TZ]#4G:7*6YO:N>82S
MO-M[=X- A?K?6,O&:M/X>#H^.3[:I?%('_S\" I.R3UY0'DSS[+]LT0I310)
MHW+;HR /=C-4B(F*GS"RQAF)U8Y.U8Z._ZYV].=R\S5>$3I"2BGY -MUVJBK
M#)JX-GM'1,+C2_8^UV:T)_ORNR.R_Z$!]7CG35CR#--WF:]'.K=]0]YWQ ]Q
M[H^T'.?)^XYT+?+_8CMK6W[SX;4?5ZHV7LM/#8MDE\D)C,3:I*JB8P3.]Y!/
M#&7=5>T\:M1+U6C.1;OM:F;,ZTQ)=+3F+Y.8)++NZ7?JPUA]R)LM__/[C,N5
MP,4JS02.,EU3WHSSD:5\8EI2R@NA?6$1]32N5$PB+J>FYVQ,B\-8A#\(OK'N
MMFPUMQ3^3E=5?'%8Y"X HPV9("G?BHB\J5?J;J&C5#K:4*E02RK"QE\7HQ]R
M#?I-J_[S:7*HQ4%'RR70=D-8MI0U6EK0+';5S393NI?K94%TLL60V<=:@I3&
M<0=?R!W':N=7%*\M]HUR5UULM:7[N%$81"?;')F]7&F0$OGJYB\DC43RK);S
M7>UHR)QWNL5DJ^]KFK 0:!N#2:AI/0WL]V2=J*E%65#GMT1M[!C& +WKH;_3
MMCD76,5!0#/$(3A;U(-0%>6)HPO&MIC>DV<NNO!IREQ38S-IPE+7!,6(Q1B(
M1J%%A=@3$?_8RC-V(NB^%XJ6TC47@%43#4,6%!UV;R @E=PO(TN!69JH :P7
MDK;4^>D&8+9UZF'H@N($, >?DE1ZOZ0L'@FEZGX 9OT#BDWLFA;8L,E+6QD4
M,: ]D)D\ I4AX6!S^:)6YW*9-+"Q-;U/>%JVN_BIQ,$B9#H<2%$>AE2<)Y)J
MMR%Z&&HI7=,#6#6Y,61!$6/W!K)2R%&N]P_))8L'(5+I_ !BV+3C48H"A*/I
MK \-J?8)QE621I@67J[DMK2C>1:M:T! NR8D+6%0H$#N0%B* ,U,'N(5F'\1
M+(;A4E/Z@:5EU8Y*)0L0%--;'R9*[P62V5:(AFMXQH&ESF[*]IBM[L\"NB!
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M3=?RD]RL-\F_5C@E<LM_ 5!+ P04    "  6A<I8X"@$E5<'  #95P  %0
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M<-9,96/.X@&7)'A=OB.#\D7,0BMLH>"](N))97,3K^Z5C"EUCT_TYF@#)$3
M"J A0<Q/7X0"YW:!3%.WF$C&3Z.9-:WO,I._P=3V+WC3(%@.&AK,19P XTA7
M0?KG0B^:7*T>Z(0J-TWAD2[-E6WH*7Q1!"@.C0_J&X7 &"K"=-XY\'5C-[AW
MU!;?N%_N/:QVR_]02P$"% ,4    "  6A<I8TTR#?M87  "P=@  &0
M        @ $     96$P,C W-3@R+3AK7VUO;VYL86ME+FAT;5!+ 0(4 Q0
M   ( !:%REATK$_/6AP  (6.   >              "  0T8  !E83 R,#<U
M.#(P,65X.3DM,5]M;V]N;&%K92YH=&U02P$"% ,4    "  6A<I8VR#92=,+
M  !F#   #0              @ &C-   :6UA9V5?,# Q+FIP9U!+ 0(4 Q0
M   ( !:%RE@F/:K(*0,  .D+   1              "  :%   !M;'1X+3(P
M,C0P-C$P+GAS9%!+ 0(4 Q0    ( !:%REA7A5WL_@H  ("&   5
M      "  ?E#  !M;'1X+3(P,C0P-C$P7VQA8BYX;6Q02P$"% ,4    "  6
MA<I8X"@$E5<'  #95P  %0              @ $J3P  ;6QT>"TR,#(T,#8Q
?,%]P<F4N>&UL4$L%!@     &  8 DP$  +16      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0207582-8k_moonlake_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mltx-20240610.xsd" xlink:type="simple"/>
    <context id="AsOf2024-06-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-06-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-06-10" id="Fact000004">0001821586</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-06-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-06-10" id="Fact000010">2024-06-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-06-10" id="Fact000011">MOONLAKE IMMUNOTHERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-06-10" id="Fact000012">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-06-10" id="Fact000013">001-39630</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-06-10" id="Fact000014">98-1711963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-06-10" id="Fact000015">Dorfstrasse 29</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-06-10" id="Fact000016">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-06-10" id="Fact000017">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2024-06-10" id="Fact000018">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2024-06-10" id="Fact000019">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-06-10" id="Fact000020">415108022</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-06-10" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-06-10" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-06-10" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-06-10" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-06-10" id="Fact000025">Class A ordinary share, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-06-10" id="Fact000026">MLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-06-10" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-06-10" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
